SEARCH:   Advanced

Blood, 15 November 2008, Vol. 112, No. 10, pp. 4017-4023. Prepublished online as a Blood First Edition Paper on July 31, 2008; DOI 10.1182/blood-2008-05-159624. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-05-159624v1 112/10/4017    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Paiva, B. Articles by San Miguel, J. F. Search for Related Content PubMed PubMed Citation Articles by Paiva, B. Articles by San Miguel, J. F. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted May 27, 2008 Accepted June 22, 2008 Multiparameter flow cytometry remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation Bruno Paiva, Maria-Belen Vidriales, Jorge Cervero, Gema Mateo, Jose J. Perez, Maria Angeles Montalban, Anna Sureda, Laura Montejano, Norma C. Gutierrez, Alfonso Garcia de Coca, Natalia de las Heras, Maria Victoria Mateos, Maria Consuelo Lopez-Berges, Raimundo Garcia-Boyero, Josefina Galende, Jose Hernandez, Luis Palomera, Dolores Carrera, Rafael Martinez, Javier de la Rubia, Alejandro Martin, Joan Blade, Juan Jose Lahuerta, Alberto Orfao, and Jesus F. San Miguel* Hospital Universitario de Salamanca, Salamanca, Spain Centro de Investigacion del Cancer (CIC, IBMCC USAL-CSIC), Salamanca, Spain Hospital 12 de Octubre, Madrid, Spain Hospital Santa Creu I Sant Pau, Barcelona, Spain Hospital Clinico Universitario de Valladolid, Valladolid, Spain Complejo Hospitalario de Leon, Leon, Spain Hospital General de Castellon, Castellon, Spain Hospital del Bierzo, Ponferrada, Spain Hospital General de Segovia, Segovia, Spain Hospital Lozano Blesa, Zaragoza, Spain Hospital Central de Asturias, Oviedo, Spain Clinico San Carlos, Madrid, Spain Hospital La Fe, Valencia, Spain Hospital Virgen de la Concha, Zamora, Spain Hospital Clinic, IDIBAPS, Barcelona, Barcelona, Spain Citometry, Servicio General de Citometria, Universidad de Salamanca, Salamanca, Spain * Corresponding author; email: sanmigiz{at}usal.es. Minimal residual disease (MRD) assessment is standard in many hematologic malignancies but is considered investigational in multiple myeloma (MM). We report a prospective analysis of the prognostic importance of MRD detection by multiparameter flow cytometry (MFC) in 295 newly diagnosed MM patients uniformly treated in the GEM2000 protocol (VBMCP/VBAD induction plus autologous stem cell transplant [ASCT]). MRD status by MFC was determined at day 100 post-ASCT. Progression-free survival (PFS; median 71 vs 37 months, P < .0001) and overall survival (OS; median not reached vs 89 months, P = .002) were longer in patients who were MRD-negative versus MRD-positive at day 100 post-ASCT. Similar prognostic differentiation was seen in 147 patients who achieved immunofixation-negative complete response post-ASCT. Moreover, patients MRD- IFx- and MRD- IFx+ patients had significantly longer PFS than MRD+ IFx- patients. Multivariate analysis identified MRD status by MFC at day 100 post-ASCT as the most important independent prognostic factor for PFS (HR = 3.64, P = .002) and OS (HR = 2.02, P = .02). Our findings demonstrate the clinical importance of MRD evaluation by MFC, and illustrate the need for further refinement of MM response criteria. This trial is registered at http://clinicaltrials.gov under identifier NCT00560053. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Going with the flow, and beyond, in myeloma Bart Barlogie, Joshua Epstein, and John D. Shaughnessy, Jr Blood 2008 112: 3917-3918. [Full Text] [PDF] This article has been cited by other articles: J.-L. Harousseau, H. Avet-Loiseau, M. Attal, C. Charbonnel, F. Garban, C. Hulin, M. Michallet, T. Facon, L. Garderet, G. Marit, et al. Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials J. Clin. Oncol., December 1, 2009; 27(34): 5720 - 5726. [Abstract] [Full Text] [PDF] B. Paiva, M.-B. Vidriales, G. Mateo, J. J. Perez, M. A. Montalban, A. Sureda, L. Montejano, N. C. Gutierrez, A. Garcia de Coca, N. de las Heras, et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients Blood, November 12, 2009; 114(20): 4369 - 4372. [Abstract] [Full Text] [PDF] B. Paiva, M.-B. Vidriales, J. J. Perez, G. Mateo, M. A. Montalban, M. V. Mateos, J. Blade, J. J. Lahuerta, A. Orfao, and J. F. San Miguel Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients Haematologica, November 1, 2009; 94(11): 1599 - 1602. [Abstract] [Full Text] [PDF] J.-L. Harousseau, M. Attal, and H. Avet-Loiseau The role of complete response in multiple myeloma Blood, October 8, 2009; 114(15): 3139 - 3146. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020